- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07475949
Okänd Tid för Insättning Stroke Reperfusion Utan Avancerad Bildgivning (UTOPIA)
Intravenös Tenekteplas för akut ischemisk stroke med okänd debuttid under selektion med icke-kontrastförstärkt DT: En multicenter, prospektiv, randomiserad, öppen, blindad slutpunktsstudie
The benefit of intravenous tenecteplase for acute ischemic stroke with unknown time of onset, e.g. wake-up stroke, remains uncertain. This randomized study aims to assess the efficacy and safety of intravenous tenecteplase following non-contrast CT screening for acute ischemic stroke with unknown time of onset.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
UTOPIA is an investigator-initiated, multicenter, prospective, randomized, open-label, blinded endpoint (PROBE) trial that aims to assess the efficacy and safety of intravenous tenecteplase for acute ischemic stroke with unknown time of onset, selected by non-contrast CT. The primary outcome is excellent outcome, as defined by a score of 0 or 1 on modified Rankin Scale (mRS) at 90 days.
Participants randomized to the intervention group will receive intravenous tenecteplase at 0.25 mg/kg with a maximum dose of 25 mg and standard medical treatment, and those randomized to the control group will receive standard medical treatment only, without intravenous thrombolysis.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 3
Kontakter och platser
Studiekontakt
- Namn: Dong Pan, MD, PhD
- Telefonnummer: 86-156 2648 3251
- E-post: dongpan012@hotmail.com
Studieorter
-
-
Fujian
-
Xiamen, Fujian, Kina, 361004
- Har inte rekryterat ännu
- Zhongshan Hospital of Xiamen University
-
Kontakt:
- Xingyu Chen
-
-
Guangdong
-
Guangzhou, Guangdong, Kina, 510620
- Har inte rekryterat ännu
- Guangzhou Twelfth People's Hospital
-
Kontakt:
- Jianwu Dai
-
-
Guangxi
-
Baise City, Guangxi, Kina, 533000
- Har inte rekryterat ännu
- Baise People's Hospital
-
Kontakt:
- Dengxing Li
-
Chongzuo, Guangxi, Kina, 532200
- Rekrytering
- The People's Hospital of Chongzuo
-
Kontakt:
- Jianyi Huang
-
Guigang, Guangxi, Kina, 537121
- Har inte rekryterat ännu
- People's Hospital of Qintang District, Guigang City
-
Kontakt:
- Jixin Lu
-
Guigang, Guangxi, Kina, 537200
- Har inte rekryterat ännu
- Guiping People's Hospital
-
Kontakt:
- Peiquan Yang
-
Laibin, Guangxi, Kina, 545900
- Har inte rekryterat ännu
- Wuxuan County People's Hospital
-
Kontakt:
- Yu Huang
-
Liuzhou, Guangxi, Kina, 545007
- Har inte rekryterat ännu
- Liuzhou Workers' Hospital
-
Kontakt:
- Liya Pan
-
Nanning, Guangxi, Kina, 530021
- Har inte rekryterat ännu
- The First Affiliated Hospital of Guangxi Medical University
-
Kontakt:
- Dong Pan, MD, PhD
- Telefonnummer: 86-156 2648 3251
- E-post: dongpan012@hotmail.com
-
Huvudutredare:
- Yuan Wu, MD, PhD
-
Nanning, Guangxi, Kina, 530200
- Har inte rekryterat ännu
- Nanning Yongning District People's Hospital
-
Kontakt:
- Wuqiao Liang
-
Kontakt:
- Qihai Zhou
-
Nanning, Guangxi, Kina, 530219
- Har inte rekryterat ännu
- Guangxi Medical University Kaiyuan Langdong Hospital
-
Kontakt:
- Kai Chen
-
Nanning, Guangxi, Kina, 530409
- Har inte rekryterat ännu
- No.9 People's Hospital of Nanning
-
Kontakt:
- Jun Qu
-
Qinzhou, Guangxi, Kina, 535000
- Har inte rekryterat ännu
- The Second People's Hospital of Qinzhou
-
Kontakt:
- Caixia Xuan
-
-
Shaanxi
-
Yulin, Shaanxi, Kina, 718100
- Har inte rekryterat ännu
- Mizhi County Hospital
-
Kontakt:
- Tao Zhang
-
Yulin, Shaanxi, Kina, 718600
- Har inte rekryterat ännu
- Dingbian County People's Hospital
-
Kontakt:
- Gaiyan Qu
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Age ≥ 18 years old.
- Clinical diagnosis of acute ischemic stroke.
- Unknown time of stroke onset (e.g., stroke symptom recognized on awakening) but last-known normal time >4.5 hours.
- Time from stroke symptom recognition (e.g., awakening) to randomization within 3 hours.
- National Institutes of Health Stroke Scale (NIHSS) score of 6-25 (both inclusive).
- Pre-stroke modified Rankin Scale (mRS) score of 0-1.
- Written informed consent from patients or their legally authorized representatives.
Exclusion Criteria:
- Intracranial hemorrhage confirmed by skull CT, or history of intracranial hemorrhage.
- Planned endovascular treatment.
- Rapid neurological improvement with NIHSS <6 at randomization.
- Allergy to tenecteplase.
- Use of vitamin K antagonist with INR >1.7, use of heparin or low molecular heparin in the past 24 hours, or use of direct oral anticoagulants in the past 48 hours.
- Hypodensity on non-contrast CT >1/3 middle cerebral artery territory.
- Severe traumatic brain injury or other major trauma in the past 3 months.
- Intracranial neoplasm, arteriovenous malformation, or aneurysm (≥10mm).
- Intracranial surgery, intraspinal surgery, or other major surgery in the past 3 months.
- Gastrointestinal or urinary tract hemorrhage in the past 3 weeks.
- Active internal bleeding.
- Aortic dissection.
- Infective endocarditis.
- Platelet count <100×10^9/L.
- Women who are pregnant or breastfeeding.
- Blood glucose <50 or >400 mg/dL (<2.78 or >22.2 mmol/L).
- Systolic blood presure >185 mmHg or diastolic blood presure >110 mmHg refractory to treatment.
- Life expectancy <3 months.
- Participating in other trials.
- Any condition that, in the judgment of the investigator, makes the patient unsuitable for this study or where this study may impose a significant risk to the patient (e.g., inability to understand and/or comply with study procedures and/or follow-up due to psychiatric disorders, cognitive or emotional impairment).
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Övrig: Control group
Standard Medical Treatment |
Standard medical treatment should adhere to clinical guidelines and usual care at site, including antiplatelet therapy, anticoagulant therapy, lipid-lowering therapy, antihypertensive drugs, etc., as determined by the local investigators. |
|
Experimentell: Tenecteplase group
Intravenous tenecteplase thrombolysis |
Standard medical treatment should adhere to clinical guidelines and usual care at site, including antiplatelet therapy, anticoagulant therapy, lipid-lowering therapy, antihypertensive drugs, etc., as determined by the local investigators. Tenecteplase is administered as a single intravenous bolus at a dose of 0.25 mg/kg, with a maximum of 25 mg, administered as soon as possible after the randomization. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Excellent outcome
Tidsram: 90 (±14) days
|
The proportion of modified Rankin Scale (mRS) score of 0-1 at 90 days |
90 (±14) days
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Level of disability
Tidsram: 90 (±14) days
|
Ordinal shift analysis of the mRS with 5-6 merged at 90 days. |
90 (±14) days
|
|
Functional independence
Tidsram: 90 (±14) days
|
The proportion of mRS score of 0-2 at 90 days. |
90 (±14) days
|
|
Early neurological improvement
Tidsram: 24 (±12) hours
|
The proportion of NIHSS 0-1 or ≥4 points reduction at 24 (±12) hours. |
24 (±12) hours
|
|
Change in stroke severity
Tidsram: 7 (±1) days or at discharge
|
The change of NIHSS score from baseline to 7 days or at discharge (whichever comes first) |
7 (±1) days or at discharge
|
|
Quality of life measured by EQ-5D-5L
Tidsram: 90 (±14) days
|
EQ-5D-5L scale score at 90 days. |
90 (±14) days
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Symptomatic intracranial hemorrhage
Tidsram: 24 (±12) hours
|
Incidence of symptomatic intracranial hemorrhage within 36 hours from randomization (Heidelberg criteria) |
24 (±12) hours
|
|
Any intracranial hemorrhage
Tidsram: 24 (±12) hours
|
Incidence of any intracranial hemorrhage within 36 hours from randomization (Heidelberg classification) |
24 (±12) hours
|
|
Extracranial bleeding
Tidsram: 24 (±12) hours
|
Incidence of moderate-to-severe extracranial bleeding (GUSTO criteria) within 36 hours from randomization |
24 (±12) hours
|
|
Mortality
Tidsram: 90 days
|
All cause death within 90 days. |
90 days
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: Yuan Wu, MD, PhD, First Affiliated Hospital of Guangxi Medical University
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Cerebrovaskulära störningar
- Hjärnsjukdomar
- Sjukdomar i centrala nervsystemet
- Sjukdomar i nervsystemet
- Kärlsjukdomar
- Hjärt-kärlsjukdomar
- Stroke
- Ischemisk stroke
- Aminosyror, peptider och proteiner
- Proteiner
- Hydrolaser
- Enzymer
- Enzymer och koenzymer
- Blodproteiner
- Endopeptidaser
- Peptidhydrolaser
- Serin endopeptidaser
- Serinproteaser
- Plasminogenaktivatorer
- Blodkoagulationsfaktorer
- Vävnadsplasminogenaktivator
- Tenecteplas
Andra studie-ID-nummer
- 2026-K0237
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Data supporting the findings of the study are available on reasonable request after approval of a proposal from the principal investigator.
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- SAV
- CSR
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .